You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBimatoprost
Accession NumberDB00905  (APRD00826, DB06863)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor.
Structure
Thumb
Synonyms
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1e,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
Bimatoprostum
External Identifiers
  • AGN 192024
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LatisseSolution / drops.3 mg/mLOphthalmicAllergan, Inc.2009-01-26Not applicableUs
LatisseSolution0.03 %TopicalAllergan Inc2010-11-01Not applicableCanada
LumiganSolution / drops.1 mg/mLOphthalmicAllergan, Inc.2010-09-10Not applicableUs
LumiganSolution / drops.3 mg/mLOphthalmicPhysicians Total Care, Inc.2001-03-22Not applicableUs
LumiganSolution / drops.1 mg/mLOphthalmicPhysicians Total Care, Inc.2011-09-14Not applicableUs
LumiganSolution0.03 %OphthalmicAllergan Inc2002-05-24Not applicableCanada
Lumigan PFSolution0.03 %OphthalmicAllergan IncNot applicableNot applicableCanada
Lumigan RcSolution0.01 %OphthalmicAllergan Inc2009-06-16Not applicableCanada
VistitanSolution0.03 %OphthalmicSandoz Canada Incorporated2016-05-13Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bimatoprostSolution0.03 %OphthalmicApotex IncNot applicableNot applicableCanada
Apo-bimatoprostSolution0.03 %TopicalApotex IncNot applicableNot applicableCanada
BimatoprostSolution / drops.3 mg/mLOphthalmicLupin Pharmaceuticals, Inc.2015-05-13Not applicableUs
BimatoprostSolution / drops.3 mg/mLOphthalmicLUPIN LIMITED2015-05-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQXS94885MZ
CAS number155206-00-1
WeightAverage: 415.5656
Monoisotopic: 415.272258677
Chemical FormulaC25H37NO4
InChI KeyAQOKCDNYWBIDND-FTOWTWDKSA-N
InChI
InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
IUPAC Name
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
SMILES
CCNC(=O)CCC\C=C/C[[email protected]]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
Pharmacology
IndicationFor the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Structured Indications
PharmacodynamicsBimatoprost is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity, that is chemically related to prostamide F. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost lowers intraocular pressure (IOP) in humans. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Mechanism of actionBimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Bimatoprost reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Bimatoprost is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. Bimatoprost may also lower the rate of aqueous formation in the eye. Both these effects decrease the pressure within the eye.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin F2-alpha receptorProteinyes
agonist
HumanP43088 details
Prostaglandin E2 receptor EP1 subtypeProteinyes
agonist
HumanP34995 details
Prostaglandin E2 receptor EP3 subtypeProteinyes
agonist
HumanP43115 details
Aldo-keto reductase family 1 member C3ProteinunknownNot AvailableHumanP42330 details
Related Articles
AbsorptionSystemically absorbed when administered to the eye.
Volume of distribution
  • 0.67 L/kg
Protein bindingApproximately 88% of bimatoprost is bound in human plasma.
Metabolism

Bimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites.

Route of eliminationUp to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.
Half lifeElimination half-life is approximately 45 minutes.
Clearance
  • 1.5 L/hr/kg [Healthy subjects receiving IV administration of 3.12 ug/kg]
ToxicityIn oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bimatoprost.Experimental
AcebutololBimatoprost may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Aceclofenac.Approved
AcetovanilloneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Acetovanillone.Investigational
Acetylsalicylic acidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Adapalene.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
AliskirenBimatoprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Bimatoprost.Approved, Withdrawn
AmbrisentanBimatoprost may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineBimatoprost may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Bimatoprost.Approved
AnisodamineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Antipyrine.Approved
ApremilastThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Apremilast.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Bimatoprost.Approved
AzapropazoneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bimatoprost.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bimatoprost.Withdrawn
BenoxaprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Benoxaprofen.Withdrawn
BepridilBimatoprost may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Bimatoprost.Approved
BethanidineBethanidine may increase the hypotensive activities of Bimatoprost.Approved
Betulinic AcidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Betulinic Acid.Investigational
BisoprololBisoprolol may increase the hypotensive activities of Bimatoprost.Approved
BosentanBosentan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BretyliumBimatoprost may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Bimatoprost.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bimatoprost.Approved
BromfenacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Bucillamine.Investigational
BupranololBimatoprost may increase the hypotensive activities of Bupranolol.Approved
CandesartanCandesartan may increase the hypotensive activities of Bimatoprost.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Bimatoprost.Experimental
CaptoprilBimatoprost may increase the hypotensive activities of Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bimatoprost.Withdrawn
CarprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bimatoprost.Approved
CarvedilolBimatoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololBimatoprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bimatoprost.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bimatoprost.Approved
CilazaprilBimatoprost may increase the hypotensive activities of Cilazapril.Approved
ClonidineClonidine may increase the hypotensive activities of Bimatoprost.Approved
ClonixinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Clonixin.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Bimatoprost.Approved
CurcuminThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Curcumin.Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Bimatoprost.Approved
D-LimoneneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with D-Limonene.Investigational
DebrisoquinBimatoprost may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineBimatoprost may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bimatoprost.Approved
DiclofenacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiflunisalThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Diflunisal.Approved
DihydralazineBimatoprost may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Bimatoprost.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bimatoprost.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Bimatoprost.Approved
DroxicamThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Bimatoprost can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ebselen.Investigational
EfonidipineBimatoprost may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Bimatoprost.Approved, Vet Approved
EnalaprilatBimatoprost may increase the hypotensive activities of Enalaprilat.Approved
EpirizoleThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Epirizole.Approved
EpoprostenolBimatoprost may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Bimatoprost.Approved
EtanerceptThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etanercept.Approved, Investigational
EtodolacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Evening primrose oil.Approved
exisulindThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with exisulind.Investigational
FelodipineBimatoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Bimatoprost.Approved
FenoprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Fenoprofen.Approved
FloctafenineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Flunixin.Vet Approved
FlurbiprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Bimatoprost.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bimatoprost.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Bimatoprost.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Bimatoprost.Approved
GuanethidineBimatoprost may increase the hypotensive activities of Guanethidine.Approved
GuanfacineBimatoprost may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumBimatoprost may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Bimatoprost can be decreased when used in combination with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Bimatoprost.Approved
HydralazineBimatoprost may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBimatoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bimatoprost.Approved
IbuprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Bimatoprost.Approved, Investigational
ImidaprilBimatoprost may increase the hypotensive activities of Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Bimatoprost.Approved
IndenololBimatoprost may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminBimatoprost may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Bimatoprost.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bimatoprost.Withdrawn
IrbesartanBimatoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bimatoprost.Approved
IsoxicamThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Bimatoprost.Approved
KebuzoneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinBimatoprost may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Bimatoprost.Approved
LacidipineBimatoprost may increase the hypotensive activities of Lacidipine.Approved
LatanoprostThe risk or severity of intraocular pressure can be increased when Latanoprost is combined with Bimatoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
LisofyllineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lisofylline.Investigational
LofexidineBimatoprost may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lornoxicam.Approved
LosartanLosartan may increase the hypotensive activities of Bimatoprost.Approved
LoxoprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanBimatoprost may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineBimatoprost may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Bimatoprost.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bimatoprost.Approved
Meclofenamic acidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Metamizole.Withdrawn
MethyldopaBimatoprost may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bimatoprost.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bimatoprost.Approved, Investigational
MetipranololBimatoprost may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Bimatoprost.Approved
MetoprololMetoprolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
MetyrosineBimatoprost may increase the hypotensive activities of Metyrosine.Approved
MibefradilBimatoprost may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Bimatoprost.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bimatoprost.Approved
MizoribineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bimatoprost.Approved
MoexiprilMoexipril may increase the hypotensive activities of Bimatoprost.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bimatoprost.Approved
MoxonidineBimatoprost may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nabumetone.Approved
NadololBimatoprost may increase the hypotensive activities of Nadolol.Approved
NafamostatThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Naftifine.Approved
NaftopidilBimatoprost may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 4016The therapeutic efficacy of Bimatoprost can be decreased when used in combination with NCX 4016.Investigational
NebivololBimatoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Bimatoprost.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Bimatoprost.Approved
NicorandilBimatoprost may increase the hypotensive activities of Nicorandil.Approved
Niflumic AcidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineBimatoprost may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBimatoprost may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Bimatoprost.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Bimatoprost.Approved
NitrendipineBimatoprost may increase the hypotensive activities of Nitrendipine.Approved
NitroaspirinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Bimatoprost.Approved
ObinutuzumabBimatoprost may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bimatoprost.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
OlopatadineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Bimatoprost.Investigational
OrgoteinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxaprozin.Approved
OxprenololBimatoprost may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxyphenbutazone.Withdrawn
ParecoxibThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Bimatoprost.Approved
PenbutololBimatoprost may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumBimatoprost may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Bimatoprost.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Bimatoprost.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bimatoprost.Withdrawn
PhenoxybenzamineBimatoprost may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bimatoprost.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Bimatoprost.Approved
PhenylbutazoneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilBimatoprost may increase the hypotensive activities of Pinacidil.Withdrawn
PindololBimatoprost may increase the hypotensive activities of Pindolol.Approved
PirfenidoneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Bimatoprost.Approved
PiroxicamThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Bimatoprost.Withdrawn
PolythiazideBimatoprost may increase the hypotensive activities of Polythiazide.Approved
PrazosinPrazosin may increase the hypotensive activities of Bimatoprost.Approved
PropacetamolThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Propacetamol.Approved
PropranololPropranolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
PTC299The therapeutic efficacy of Bimatoprost can be decreased when used in combination with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Bimatoprost.Approved
RamiprilRamipril may increase the hypotensive activities of Bimatoprost.Approved
RasagilineRasagiline may increase the hypotensive activities of Bimatoprost.Approved
RemikirenRemikiren may increase the hypotensive activities of Bimatoprost.Approved
RescinnamineBimatoprost may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bimatoprost.Approved
ResveratrolThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineBimatoprost may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatBimatoprost may increase the hypotensive activities of Riociguat.Approved
RituximabBimatoprost may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Bimatoprost.Withdrawn
SalicylamideThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salsalate.Approved
SaprisartanBimatoprost may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Bimatoprost.Approved, Investigational, Vet Approved
SelexipagBimatoprost may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Seratrodast.Approved, Investigational
SildenafilSildenafil may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
SitaxentanBimatoprost may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilBimatoprost may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Bimatoprost can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
TelmisartanBimatoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilBimatoprost may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Teriflunomide.Approved
TerlipressinBimatoprost may increase the hypotensive activities of Terlipressin.Approved, Investigational
Tiaprofenic acidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneBimatoprost may increase the hypotensive activities of Tibolone.Approved
TicrynafenBimatoprost may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Bimatoprost.Approved
TinoridineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tinoridine.Investigational
TolazolineTolazoline may increase the hypotensive activities of Bimatoprost.Approved, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Bimatoprost.Approved
TorasemideTorasemide may increase the hypotensive activities of Bimatoprost.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Bimatoprost.Approved
TranilastThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bimatoprost.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Bimatoprost.Approved
TravoprostTravoprost may increase the hypotensive activities of Bimatoprost.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bimatoprost.Approved, Investigational
TrichlormethiazideBimatoprost may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinBimatoprost may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanBimatoprost may increase the hypotensive activities of Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
UnoprostoneBimatoprost may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bimatoprost.Approved
VinpocetineBimatoprost may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineBimatoprost may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bimatoprost.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Jiang Xing Chen, “Process for the production of intermediates for making prostaglandin derivatives such as latanaprost, travaprost, and bimatoprost.” U.S. Patent US20090287003, issued November 19, 2009.

US20090287003
General References
  1. Chen MJ, Cheng CY, Chen YC, Chou CK, Hsu WM: Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma. J Ocul Pharmacol Ther. 2006 Jun;22(3):188-93. [PubMed:16808680 ]
  2. Kruse P, Rieck P, Sherif Z, Liekfeld A: [Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?]. Klin Monbl Augenheilkd. 2006 Jun;223(6):534-7. [PubMed:16804825 ]
  3. Steinhauser SL: Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy. Optometry. 2006 Apr;77(4):177-9. [PubMed:16567279 ]
  4. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ: The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45. [PubMed:11434936 ]
  5. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763 ]
  6. Brubaker RF: Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S347-51. [PubMed:11434937 ]
  7. Christiansen GA, Nau CB, McLaren JW, Johnson DH: Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004 Sep;111(9):1658-62. [PubMed:15350319 ]
  8. Easthope SE, Perry CM: Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002;19(3):231-48. [PubMed:12027782 ]
  9. Patil AJ, Vajaranant TS, Edward DP: Bimatoprost - a review. Expert Opin Pharmacother. 2009 Nov;10(16):2759-68. doi: 10.1517/14656560903292649. [PubMed:19874254 ]
External Links
ATC CodesS01EE03
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (24.4 KB)
MSDSDownload (19.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9975
Blood Brain Barrier+0.825
Caco-2 permeable-0.5699
P-glycoprotein substrateSubstrate0.5541
P-glycoprotein inhibitor INon-inhibitor0.8671
P-glycoprotein inhibitor IINon-inhibitor0.8616
Renal organic cation transporterNon-inhibitor0.8078
CYP450 2C9 substrateNon-substrate0.7703
CYP450 2D6 substrateNon-substrate0.7406
CYP450 3A4 substrateSubstrate0.552
CYP450 1A2 substrateNon-inhibitor0.6764
CYP450 2C9 inhibitorNon-inhibitor0.7695
CYP450 2D6 inhibitorNon-inhibitor0.6384
CYP450 2C19 inhibitorNon-inhibitor0.7632
CYP450 3A4 inhibitorNon-inhibitor0.757
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.7646
CarcinogenicityNon-carcinogens0.9257
BiodegradationNot ready biodegradable0.6415
Rat acute toxicity2.1085 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9251
hERG inhibition (predictor II)Non-inhibitor0.7822
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Allergan inc
Packagers
Dosage forms
FormRouteStrength
SolutionTopical0.03 %
Solution / dropsOphthalmic.3 mg/mL
SolutionOphthalmic0.03 %
Solution / dropsOphthalmic.1 mg/mL
SolutionOphthalmic0.01 %
Prices
Unit descriptionCostUnit
Lumigan .03% 7.5ml Bottle279.56USD bottle
Lumigan .03% 5ml Bottle171.4USD bottle
Lumigan .03% 2.5ml Bottle91.16USD bottle
Lumigan 0.03% eye drops44.82USD ml
Latisse 0.03% eyelash solution36.0USD ml
Lumigan 0.03 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2144967 No2003-11-112013-09-09Canada
CA2585691 No2009-05-192026-03-14Canada
US6403649 No1992-09-212012-09-21Us
US7351404 No2004-05-252024-05-25Us
US7388029 No2002-01-212022-01-21Us
US7851504 No2007-06-132027-06-13Us
US8038988 No2003-08-252023-08-25Us
US8101161 No2004-05-252024-05-25Us
US8263054 No2003-01-152023-01-15Us
US8278353 No2005-03-162025-03-16Us
US8299118 No2005-03-162025-03-16Us
US8309605 No2005-03-162025-03-16Us
US8338479 No2005-03-162025-03-16Us
US8524777 No2005-03-162025-03-16Us
US8541466 No2001-01-312021-01-31Us
US8586630 No2005-03-162025-03-16Us
US8632760 No2003-01-152023-01-15Us
US8758733 No2003-01-152023-01-15Us
US8772338 No2005-03-162025-03-16Us
US8906962 No2001-01-312021-01-31Us
US8926953 No2003-01-152023-01-15Us
US8933120 No2005-03-162025-03-16Us
US8933127 No2005-03-162025-03-16Us
US8986715 No2003-01-152023-01-15Us
US9155716 No2005-03-162025-03-16Us
US9216183 No2003-01-152023-01-15Us
US9226931 No2003-01-152023-01-15Us
US9241918 No2005-03-162025-03-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0187 mg/mLALOGPS
logP3.41ALOGPS
logP2.63ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.35ChemAxon
pKa (Strongest Basic)-0.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area89.79 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity122.83 m3·mol-1ChemAxon
Polarizability48.99 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Cyclopentanol
  • Monocyclic benzene moiety
  • Cyclic alcohol
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin f receptor activity
Specific Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and ...
Gene Name:
PTGFR
Uniprot ID:
P43088
Molecular Weight:
40054.1 Da
References
  1. Sharif NA, Williams GW, Kelly CR: Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 2001 Dec 7;432(2-3):211-3. [PubMed:11740958 ]
  2. Sharif NA, Kelly CR, Crider JY: Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002 Aug;18(4):313-24. [PubMed:12222762 ]
  3. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. [PubMed:14733708 ]
  4. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763 ]
  5. Mintz EE: Group supervision: an experiential approach. Int J Group Psychother. 1978 Oct;28(4):467-9. [PubMed:689791 ]
  6. Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines]. Oftalmologia. 2009;53(2):3-7. [PubMed:19697832 ]
  7. Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, Wang JW, Kharlamb AB, Wheeler LA, Garst ME, Landsverk KJ, Struble CS, Stamer WD: Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4107-15. [PubMed:17724194 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin e receptor activity
Specific Function:
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.
Gene Name:
PTGER1
Uniprot ID:
P34995
Molecular Weight:
41800.655 Da
References
  1. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. [PubMed:14733708 ]
  2. Ota T, Aihara M, Saeki T, Narumiya S, Araie M: The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3395-9. [PubMed:16877408 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Rna polymerase ii transcription factor activity, ligand-activated sequence-specific dna binding
Specific Function:
Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition of sodium and water reabsorption in kidney tubulus and contraction in uterine smooth muscle. The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G-I protei...
Gene Name:
PTGER3
Uniprot ID:
P43115
Molecular Weight:
43309.335 Da
References
  1. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. [PubMed:14733708 ]
  2. Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL: Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8. doi: 10.1089/jop.2008.0089. [PubMed:19232013 ]
  3. Ota T, Aihara M, Saeki T, Narumiya S, Araie M: The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3395-9. [PubMed:16877408 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function:
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms andro...
Gene Name:
AKR1C3
Uniprot ID:
P42330
Molecular Weight:
36852.89 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:51